AIDX
20/20 Biolabs, Inc. Common Stock
There isn't enough reported data to score AIDX yet.
AIDX Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Weak | |
| Unavailable |
AIDX's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
AIDX PE Valuation
AIDX has no meaningful PE right now: it lost money over the past year.
AIDX Forward outlook
There aren't enough analyst estimates for AIDX to show an outlook.
AIDX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.84 | -$0.03 |
AIDX lost $0.84 per share over the past year, about the same as its loss the year before.
AIDX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $730.6K | +37% |
| Q1 2026 | $353.4K | -36% |
| Q4 2025 | $538.3K | +0.4% |
| Q3 2025 | $418K | +16% |
AIDX's revenue has held roughly level: $730,571 last quarter, up 37% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -170% | -12 points |
| Q1 2026 | -408% | -269 points |
| Q4 2025 | -170% | +63 points |
| Q3 2025 | -191% | +332 points |
| Q2 2025 | -158% | N/A |
| Q1 2025 | -139% | N/A |
| Q4 2024 | -232% | N/A |
| Q3 2024 | -524% | +2.4 points |
AIDX's operating margin was −170% last quarter, down 12 points from the same quarter a year ago.
AIDX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$605.5K | -$71.4K |
| Q1 2026 | -$1.3M | -$800.7K |
| Q4 2025 | -$511.7K | +$24.8K |
| Q3 2025 | -$385.7K | +$196.7K |
AIDX has burned cash in almost every quarter: −$3M over the past year, against −$2M the year before.
AIDX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +41% | +3.1M shares |
| 1 year | +4.3% | +443K shares |
AIDX has 11M diluted shares, up 4.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2023 | — |
| Q1 2023 | — |
AIDX Net Leverage
AIDX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
AIDX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 1.2 | Oversold |
| Stochastic | 2.8 | Oversold |
AIDX's weekly RSI is 1 (oversold) and its Stochastic is 3 (oversold).
AIDX PE vs Healthcare Sector
AIDX has no meaningful PE right now: it lost money over the past year.
AIDX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.29 | 31% below |
| 20 week MA | $0.44 | 55% below |
AIDX is in a downtrend: it's below all two of its weekly moving averages, and 55% below its 20-week average.
AIDX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2026 YTD | $14.8 | $0.20 | -99% |
It's down 99% so far in 2026.